A multicenter randomized controlled study of bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang in the treatment of patients newly diagnosed with Helicobacter pylori infection and dyspepsia
杜勤,杨平,时昭红,曹志群,陈光侠,王曼彤,李天望,金海峰,吕宾,陈东风,范一宏,甘淳,霍晓辉,唐秀芬,沙卫红,孟杰,马盼盼,查安生,孟立娜,李岩
DOI: https://doi.org/10.3760/cma.j.cn112137-20210305-00563
2021-01-01
Abstract: To investigate the () eradication rate and improvement of dyspepsia in patients who were newly diagnosed with infection and dyspepsia and treated by bismuth-containing quadruple therapy followed by Jing-Hua-Wei-Kang(JHWK). Patients who were newly diagnosed with dyspepsia and infection and treated in 16 medical centers in China between December 1, 2017 and September 30, 2019 were randomly divided into two groups. The experimental group received bismuth-containing quadruple therapy (esomeprazole+amoxicillin+furazolidone+colloidal bismuth pectin capsule, 14 days), followed by JHWK (30 days), and the course of treatment was 44 days in total. In the control group, the administration regimen was bismuth-containing quadruple therapy (esomeprazole+amoxicillin+furazolidone+colloidal bismuth pectin capsule, 14 days). The main outcome measure was eradication rate, while the secondary outcome measures were dyspepsia symptom changes and adverse events during the treatment and the 1st month after treatment. A total of 1 054 patients were included in the study. There were 522 cases enrolled in the experimental group, including 224(42.91%) men and 298(57.09%) women, and the age was 53(26, 73) years old; 532 cases enrolled in the control group, including 221(41.54%) men and 311(58.46%) women, and the age was 46(22, 71) years old. Based on PP analysis, it was found that the eradication rate in the experimental group was significantly higher than those in the control group (93.85% vs 87.88%, =0.001). In the group of all enrolled patients, the symptom dyspepsia after eradication was significantly improved compared with that before treatment [4(4, 7) vs 15(10, 22), <0.001], so was the superior and middle abdominal pain [1(1, 4) vs 4(1, 8), <0.001], the postprandial fullness [1(1, 4) vs 4(4, 9), <0.001], the early satiety [1(1, 1) vs 4(1, 4), <0.001], and the heartburn [1(1, 1) vs 1(1, 4), <0.001]. The symptom dyspepsia after treatment was significantly improved compared with that before treatment in the experimental, the control groups, the successful and the unsuccessful eradication groups. The superior and middle abdominal pain after treatment was signifcantly improved than that before treatment [1(1, 2) vs 1(1, 4), <0.001], so were the postprandial fullness [1(1, 3) vs 1(1, 4), =0.002] and the dyspepsia[4(4, 7) VS 7(4, 10), <0.001]. There was no statistically significant difference in the incidence of adverse events between the experimental group and the control group (1.34% vs 0.38%, =0.09). Compared with bismuth-containing quadruple therapy, bismuth-containing quadruple therapy followed by JHWK significantly improves the eradication rate without increasing the incidence of adverse events. eradication therapy can improve symptoms of patients with infection and dyspepsia.